Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04477512
Title Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine

prostate cancer


Abiraterone + Cabozantinib + Nivolumab + Prednisone

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.